We propose that the normal adrenarche-related rise in dehydroepiandrosterone (DHEA) secretion is ultimately caused by the rise in cortisol production occurring during childhood and adolescent growth, by the following mechanisms. (1) The onset of childhood growth leads to a slight fall in serum cortisol concentration due to growth-induced dilution and a decrease in the negative feedback of cortisol upon ACTH secretion. (2) In response, ACTH rises and stimulates increased cortisol synthesis and secretion in the growing body to restore the serum cortisol concentration to normal. (3) The cortisol concentration produced within and taken up by adrenocortical steroidogenic cells may rise during this time. (4) Cortisol competitively inhibits 3β-hydroxysteroid dehydrogenase type 2 (3βHSD2)-mediated conversion of 17αOH-pregnenolone to cortisol, causing a further fall in serum cortisol, a further decrease in the negative feedback of cortisol upon ACTH, a further rise in ACTH, and further stimulation of adrenal steroidogenesis. (5) The cortisol-mediated inhibition of 3βHSD2 also blocks the conversion of DHEA to androstenedione, causing a rise in adrenal DHEA and DHEA sulfate relative to androstenedione secretion. Thus, the combination of normal body growth plus inhibition of 3βHSD2 by intra-adrenal cortisol may cause normal adrenarche. Childhood obesity may hasten this process by causing a pathologic increase in body size that triggers these same processes at an earlier age, resulting in the premature onset of adrenarche.
Introduction
In 1947, Fuller Albright [1] introduced the term "adrenarche" to describe the initiation of dehydroepiandrosterone (DHEA) and DHEA sulfate secretion from the zona reticularis of the adrenal gland during childhood, first documented by Talbot et al. [2] in 1943 as a rise in urinary 17-ketosteroid secretion. Adrenarche is a gradual process beginning during early childhood [3, 4] . Premature adrenarche is a common pediatric disorder, usually benign but occasionally the harbinger of an adrenal tumor or enzyme deficiency. In some children, premature adrenarche may precede the polycystic ovarian syndrome or the metabolic syndrome [5] .
Despite decades of research, the trigger for adrenarche remains unknown. A pituitary factor, analogous to ACTH, which initiates adrenal secretion of DHEA, has been sought [6] but not found [7] . As blood concentrations of cortisol remain constant during adrenarche while DHEA levels rise 5-to 10-fold, cortisol has not been thought to play a role in initiating adrenarche [8] . The rise in adrenal DHEA secretion could be due to its increased synthesis, controlled by the enzyme 17,20-lyase, or decreased metabolism, controlled by the enzymes 3β-hydroxysteroid dehydrogenase type 2 (3βHSD2) and DHEA sulfotransferase (SULT2A1). The activity of 17,20-lyase is enhanced by both its phosphorylation [9] , as well as by the presence in the zona reticularis of cytochrome b5 [10] , an allosteric cofactor [11] , and P450 oxidoreductase, an electron donor [12] , all of which facilitate electron transfer [13] . However, none of these factors has been shown to initiate adrenarche [14] . Both older children [15] and adults [16] have a decreased expression of 3βHSD2 in the zona reticularis, but it is not known whether this is an initiating or later event. Loss-of-function mutations in the gene encoding PAPS synthase, a cofactor for SULT2A1, cause premature adrenarche [17] , although changes in the activity of neither PAPSS2 nor SULT2A have been shown to initiate adrenarche.
Although the average serum cortisol concentration remains constant throughout life, its daily production rate increases several-fold during the transition into adulthood [18] . As the relative increase in adrenal weight is approximately one third that of body weight during childhood [19] [20] [21] , we reasoned that the concentration of intra-adrenal cortisol likely rises as children grow, due to the increase in hormone production without a proportionate increase in adrenal gland size to match the increase in body size. A rise in intra-adrenal cortisol has previously been hypothesized on theoretical grounds to trigger adrenarche [22] . Winter and his colleagues [23] had considered that inhibition of 3βHSD2 by intra-adrenal steroids might contribute to the initiation of adrenarche, but showed no effect with 1 μM cortisol, the highest dose they tried despite their previously finding a 50-fold higher cortisol concentration in adrenal homogenates [24] . During the same period, Rabe et al. [25] showed that cortisol inhibited human placental 3βHSD1 activity by 50%, and found the inhibitory effect of cortisone to be much more potent. Further, treatment of primary cultures of human fetal adrenal cells with high concentrations of glucocorticoid leads to increased DHEA secretion [26] . These observations led us to ask whether cortisol regulates the synthesis and secretion of DHEA in human adrenocortical cells and might play a role in initiating human adrenarche.
Cortisol Competitively Inhibits Adrenal 3βHSD2
We performed cell-based studies [27] by growing either NCI-H295R human adrenal cells or COS-7 monkey kidney cells in tissue culture. Full-length complementary DNAs encoding human CYP17A1 or HSD3β2 were synthesized, cloned into expression vectors, and transiently transfected into COS-7 cells. To investigate the effect of cortisol on steroidogenic enzyme activity, these COS-7 cells or NCI-H295R cells were treated with the radiolabeled steroid precursors, [ 3 H]-pregnenolone or [ 3 H]-DHEA. DHEA in media was measured by ELISA and radioimmunoassay. DHEA and androstenedione in media were also measured by liquid chromatography-tandem mass spectroscopy. Tritiated steroids in media were separated by thin-layer chromatography and detected and quantified using a phosphorImager or X-ray film. We also studied the regulation of purified human 3βHSD2 by adrenal steroids under cell-free conditions [28] .
NCI-H295R cells contain all of the enzymes and steroids of the human adrenal gland [29, 30] . We found that cortisol stimulated DHEA secretion in a dose-dependent manner at concentrations ≥50 µM but had no effect at lower concentrations (Fig. 1a) . The increase in DHEA secretion was accompanied by a fall in androstenedione secretion, indicating that cortisol was acting to inhibit 3βHSD2 activity (Fig. 1b) . Surprisingly, the onset of DHEA secretion occurred within 30 min after the addition of cortisol, more rapidly than expected for a transcriptional mechanism (Fig. 1c) . We reasoned that if cortisol was working through a glucocorticoid receptordependent transcriptional mechanism, glucocorticoid receptor agonists would have a similar effect. However, neither dexamethasone nor prednisolone, both potent mediators of glucocorticoid-dependent transcription, stimulated DHEA secretion, whereas cortisone and 11-deoxycortisol, transcriptionally inactive and weakly active glucocorticoids, respectively, were even more potent than cortisol [27] . Finally, measurement of mRNAs encoding the two key regulators of adrenal androgen steroidogenesis, CYP17 and 3βHSD2, revealed no significant differences in either mRNA following cortisol treatment of NCI-H295R cells [27] . These somewhat surprising results indicated that stimulation of DHEA secretion is not mediated by a transcriptional mechanism: its onset is rapid; the required concentration of cortisol is much greater than that needed to activate the glucocorticoid receptor (∼1 nM); dexamethasone and prednisolone are inactive, whereas cortisone and 11-deoxycortisol are more active than cortisol; it occurs with no changes in CYP17A1 or HSD3B2 mRNA levels; and, as discussed subsequently, cortisol stimulates DHEA secretion from COS-7 cells, which lack glucocorticoid receptors. Interestingly, the steroids which increase DHEA secretion from NCI-H295R cells uniquely share a single A ring (Δ4) double bond with androstenedione, the end product of DHEA metabolism by 3βHSD2, whereas those steroids which do not increase DHEA secretion possess two A ring double bonds (Δ1 and Δ4) (Fig. 2) . The high degree of structural similarity among cortisol, cortisone, and 11-deoxycortisol, despite their divergent transcriptional activities, suggests that they may stimulate DHEA secretion via direct interaction with an enzyme in the adrenal androgen biosynthetic pathway, rather than through a glucocorticoid-receptor-mediated mechanism. This, as well as the decreased androstenedione/DHEA ratio following cortisol treatment of NCI-H295R cells, is consistent with the possibility that cortisol may inhibit 3βHSD2 activity via competition with end product androstenedione.
We next sought more direct evidence for the enzyme(s) whose activity is affected by cortisol to mediate the rise in DHEA secretion from human adrenal cells using pathway analysis with tritiated steroid precursors. We considered two possible mechanisms to explain the effect of cortisol on DHEA secretion from NCI-H295R cells: stimulation of 17,20-lyase or inhibition of 3βHSD2. We first analyzed the effect of cortisol on 17,20-lyase function. Using [ 3 H]-pregnenolone, we found only a modest (1.3-fold) stimulation of 17,20-lyase conversion of 17αOH-pregnenolone to DHEA [27] , which is unlikely to account for the 4-to 10-fold stimulation of DHEA secretion by cortisol. In contrast, using [ 3 H]-DHEA as the substrate, we found a 7-fold reduction in enzymatic activity of 3βHSD2-catalyzed conversion of DHEA to androstenedione (Fig. 3) , and an 8-fold inhibition of 17αOH-pregnenolone conversion to 17αOH-progesterone [27] following cortisol treatment.
To more specifically determine if the nature of the inhibitory effect of cortisol on 3βHSD2 was competitive, we expressed HSD3B2 in COS-7 monkey kidney cells, which express neither steroidogenic enzymes nor glucocorticoid receptor [31] [32] [33] , and examined Michaelis-Menten kinet- ics. Untransfected cells which lack 3βHSD2 cannot convert [ 3 H]-DHEA to androstenedione (Fig. 4) . Following transient transfection with HSD3B2, DHEA was converted to androstenedione, and cortisol competitively inhibited this activity, revealed by Dixon plot analysis, which indicated a K i for cortisol of ∼36 μM (Fig. 4) . This is more than 20 times greater than the K m for DHEA (1.6 μM) [34] . Because glucocorticoid receptor is absent from COS-7 cells, the inhibitory effect of cortisol upon 3βHSD2 is clearly mediated by a glucocorticoid receptor-independent mechanism. We found no stimulatory effect of cortisol upon the 17α-hydroxylase and 17,20-lyase activities of CYP17 using COS-7 cells transfected with CYP171A [27] . When we evaluated the ability of cortisol to inhibit purified human 3βHSD2 conversion of DHEA to androstenedione, we observed uncompetitive inhibition only at very high, nonphysiological concentrations (> 500 μM), whereas androstenedione showed the expected competitive end product inhibition upon its substrate at physiological concentrations (6 μM) [28] .
Implications of Cortisol Inhibition of Adrenal 3βHSD2
Cortisol, in physiologically relevant concentrations present in the human adrenal, is capable of marked competitive inhibition of adrenal 3βHSD2. We hypothesize that by this mechanism, it may participate in the initiation of adrenarche.
Others have wondered whether cortisol might have such a role in adrenarche, including by inhibition of 3βHSD2. Anderson [22] suggested almost 40 years ago that adrenarche was triggered by a rise in intra-adrenal cortisol, which might occur due to a hypothetical agedependent change in intra-adrenal blood flow leading to induction of 17,20-lyase and perhaps partial loss of 3βHSD2 activity. He believed that it was not due to any differences between cortisol production in children and adults, although it was known [18] and later confirmed [35, 36] that cortisol production increases several-fold with growth in body size. Winter and his colleagues [23] had considered that inhibition of 3βHSD2 by intra-adrenal steroids might contribute to the initiation of adrenarche, but showed no effect on enzyme activity with 1 μM cortisol, the highest dose they tried despite their previously finding a 50-fold higher cortisol concentration in adrenal homogenates [24] . During the same period, others [25] showed that cortisol, in amounts used in our study, inhibited human placental 3βHSD1 activity by 50%, and as we demonstrated for adrenal 3βHSD2, found the inhibitory effect of cortisone to be much more potent. How a rise in intra-adrenal cortisol might initiate adrenarche is depicted in Figure 5 . Diurnal variation in blood cortisol levels are similar throughout childhood and adulthood, but (1) in response to body growth, blood cortisol falls slightly due to growth-induced dilution, leading to (2) a rise in ACTH and (3) an increase in total cortisol production in the growing body. Increased ACTH would also (4) stimulate 17,20-lyase and zona reticularis growth. Before the onset of adrenarche, we suggest that the intra-adrenal cortisol is insufficient to inhibit 3βHSD2 (blue boxed arrows), directing steroidogenesis along the cortisol pathway, resulting in little DHEA synthesis. The increase in cortisol production would raise the intra-adrenal cortisol concentration. Cortisol in high concentrations is a competitive inhibitor of 3βHSD2, causing (5) decreased conversion of DHEA to androstenedione and of 17αOH-pregnenolone to cortisol. The net result would be a rise in serum DHEA, a fall in androstenedione, and a transient fall in serum cortisol. Decreased negative feedback of cortisol upon ACTH would result in (6) a further increase in ACTH leading to more adrenal stimulation, restoration of cortisol levels to normal, as well as further rise in DHEA secretion and the physiological manifestations of adrenarche. Childhood obesity may hasten this process by causing a pathologic increase in body size that triggers these same processes at an earlier age, resulting in the premature onset of adrenarche.
In other words, we propose that normal adrenarche is a state of mild, physiological 3βHSD2 deficiency, including secondary activation of the pituitary-adrenal axis. Many investigators have observed an increase in adrenal 17,20-lyase activity, determined by enzyme substrate/ product ratios during adrenarche [3, 4, 37, 38] , and much effort has therefore been focused on the regulation of this enzyme [14] . On the other hand, several investigators have documented decreased activity of 3βHSD2 determined by substrate product ratios during adrenarche [4, [38] [39] [40] [41] . We found that cortisol caused a marked stimulation of adrenal DHEA secretion by competitively inhibiting 3βHSD2, without a significant effect on 17,20-lyase. However, we hypothesize that in vivo, in response to a decreased negative feedback on ACTH caused by both growth-induced dilution of blood cortisol and by intraadrenal inhibition of cortisol synthesis, ACTH would rise. This postulated increase in ACTH would stimulate 17,20-lyase activity due to increased delivery of its substrate, 17αOH-pregnenolone, and possibly due to increased CYP17A1 transcription [42] . This rise in ACTH might also be responsible for the growth in the size of the zona reticularis during adrenarche [21, 43] . Although ACTH dynamics during childhood growth have not been studied, there is a strong positive correlation between ACTH secretion and body size in adults [44] . This hypothesis of initiation of adrenarche is consistent with many observations: 1. adrenarche is a gradual process [3, 4] , dependent on childhood growth [45] [54] , but also because high intra-adrenal levels of cortisone in this disease might contribute by inhibiting 3βHSD2 activity, further stimulating ACTH and blocking conversion of DHEA to androstenedione. Unexplained by our hypothesis is the profound reduction in 3βHSD2 protein [15, 16] and mRNA [55] during the adrenarchal process.
In summary, cortisol stimulates DHEA production in adrenal cells through inhibition of 3βHSD2 activity and may be a major regulator of adrenarche. Further studies in children are needed to determine if intra-adrenal cortisol actually increases during adrenarche, whether an early or more marked rise in intra-adrenal cortisol is responsible for benign premature adrenarche, and to provide a way to distinguish these patients from those with more serious adrenal pathologies.
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